Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations-Reference-Cited by-同舟云学术

Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations

Published:2022-12 Issue:6 Volume:7 Page:100641
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Murugesan K.,Necchi A.,Burn T.C.,Gjoerup O.,Greenstein R.,Krook M.,López J.A.,Montesion M.,Nimeiri H.,Parikh A.R.,Roychowdhury S.,Schwemmers S.,Silverman I.M.,Vogel A.

Funder

F. Hoffmann-La Roche

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference43 articles.

1. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance;Krook;Br J Cancer,2021

2. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing;Helsten;Clin Cancer Res,2016

3. Erdafitinib in locally advanced or metastatic urothelial carcinoma;Loriot;N Engl J Med,2019

4. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement;Javle;J Clin Oncol,2021

5. Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202;Vogel;Ann Oncol,2022

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas;2024-08-28

2. Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies;Clinical and Translational Oncology;2024-08-15

3. Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers;JCO Precision Oncology;2024-08

4. Identification of mechanism of the oncogenic role of FGFR1 in papillary thyroid carcinoma;European Journal of Histochemistry;2024-07-22

5. The roles of FGFR3 and c-MYC in urothelial bladder cancer;Discover Oncology;2024-07-20